ndrostanazol

ndrostanazol - Names and Identifiers

Name	Stanozolol
Synonyms	Stanzolol Stanazolol Stanozolol Winstrol l ndrostanazol Stanozolol CIII (200 mg) Stanozolol(Winstrol, Winstrol Depot) Stanozolol Suspension (For Injection) 17beta-Hydroxy-17-methyl-5alpha-androstano[3,2-c]pyrazole 2-c)pyrazol-17beta-ol,17-methyl-2'h-5alpha-androst-2-eno( 17-alpha-methyl-5-alpha-androstano(3,2-c)pyrazol-17-beta-ol 2'H-5alpha-Androst-2-eno(3,2-c)pyrazol-17beta-ol, 17-methyl- 2-c)pyrazol-17-ol,17-methyl-,(5alpha,17beta)-2'h-androst-2-eno( 2'H-Androst-2-eno[3,2-c]pyrazol-17-ol, 17-methyl-, (5alpha,17beta)- 1,10a,12a-trimethyl-1,2,3,3a,3b,4,5,5a,6,7,10,10a,10b,11,12,12a-hexadecahydrocyclopenta[5,6]naphtho[1,2-f]indazol-1-ol (1S,3aS,3bR,5aS,10aS,10bS,12aS)-1,10a,12a-trimethyl-1,2,3,3a,3b,4,5,5a,6,7,10,10a,10b,11,12,12a-hexadecahydrocyclopenta[5,6]naphtho[1,2-f]indazol-1-ol
CAS	10418-03-8
EINECS	233-894-8
InChI	InChI=1/C21H32N2O/c1-19-11-13-12-22-23-18(13)10-14(19)4-5-15-16(19)6-8-20(2)17(15)7-9-21(20,3)24/h12,14-17,24H,4-11H2,1-3H3,(H,22,23)/t14-,15+,16-,17-,19-,20-,21-/m0/s1
InChIKey	LKAJKIOFIWVMDJ-IYRCEVNGSA-N

ndrostanazol - Physico-chemical Properties

Molecular Formula	C21H32N2O
Molar Mass	328.49
Density	1.129±0.06 g/cm3(Predicted)
Melting Point	242 °C
Boling Point	490.8±45.0 °C(Predicted)
Specific Rotation(α)	34 º
Flash Point	-2℃
Solubility	Practically insoluble in water, soluble in dimethylformamide, slightly soluble in ethanol (96 per cent), very slightly soluble in methylene chloride.
Vapor Presure	1.89E-10mmHg at 25°C
Appearance	powder
Color	white to light yellow
Merck	8794
pKa	15.15±0.60(Predicted)
Storage Condition	2-8°C
Refractive Index	34 ° (C=0.4, CHCl3)
Physical and Chemical Properties	Specific optical rotation: 34 °
Use	For chronic wasting disease, serious illness and postoperative weakness emaciation, frail elderly, osteoporosis, children with dysplasia, aplastic anemia, etc

ndrostanazol - Risk and Safety

Risk Codes	R63 - Possible risk of harm to the unborn child R38 - Irritating to the skin R19 - May form explosive peroxides R11 - Highly Flammable R61 - May cause harm to the unborn child R60 - May impair fertility
Safety Description	S53 - Avoid exposure - obtain special instructions before use. S22 - Do not breathe dust. S36/37/39 - Wear suitable protective clothing, gloves and eye/face protection. S36 - Wear suitable protective clothing. S26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. S45 - In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.)
UN IDs	UN2252 - class 3 - PG 2 - 1,2-Dimethoxyethane solution
WGK Germany	3
RTECS	BV8741000
HS Code	29372900

ndrostanazol - Standard

Authoritative Data Verified Data

This product is 17-methyl -2 'H-5a-androsten-2-ene-[3,2-c] pyrazol-17b-ol. Calculated as dried product, the content of C21H32N20 shall not be less than 98.0%.

Last Update：2024-01-02 23:10:35

ndrostanazol - Trait

Authoritative Data Verified Data

This product is white crystalline powder; Odorless; Slightly hygroscopic.
This product is slightly soluble in ethanol or chloroform, slightly soluble in ethyl acetate or acetone, very slightly soluble in benzene, almost insoluble in water or methanol.

specific rotation

take this product, precision weighing, plus anhydrous ethanol dissolution and quantitative dilution of about 20mg per lml solution, according to the law (General 0621), the specific rotation was 34 ° to 40 °.

Last Update：2022-01-01 11:42:04

ndrostanazol - Differential diagnosis

Authoritative Data Verified Data

take about 2mg of this product, add 3ml of p-dimethylaminobenzaldehyde test solution, appear yellow-green, put the UV lamp (365nm) under the inspection, show yellow-green fluorescence.
take this product, add anhydrous ethanol to dissolve and dilute to make a solution containing about 40ug per lml, and measure by UV-Vis spectrophotometry (General 0401), there is a maximum absorption at a wavelength of 224nm.
The infrared absorption spectrum of this product should be consistent with that of the control (Spectrum set 597).

Last Update：2022-01-01 11:42:04

ndrostanazol - Exam

Authoritative Data Verified Data

Related substances

take this product, add dichloromethane-anhydrous ethanol (9:1) dissolved and diluted to make a solution containing 10 mg per 1ml, as a solution for the test sample; Take appropriate amount of precision, the solutions containing l0ug, 30ug and 50ug in each lml were prepared by diluting with dichloromethane-anhydrous ethanol (9:1), respectively, as a series of control solutions; add dichloromethane-absolute ethanol (9:1) to the control of stanozolol and methanolide (impurity I). Dissolve and dilute to prepare a solution containing 10 mg of stanozolol and methylprednisolone per 1ml. 1 mg solution, as a control solution. According to the thin layer chromatography (General 0502) test, absorb 10 u1 of each of the above 5 solutions, respectively point on the same silica gel G thin layer plate, with chloroform-methanol (19:1) as the developing solvent, spread out, dry, spray with 20% sulfuric acid ethanol solution, heated at 100°C for 10~15 minutes until the spots are clear, and set the UV lamp (365nm) to view. The control solution should show two clearly separated spots. If the test solution shows impurity spots, compared with the main spots of the series of control solutions, the total amount of impurities shall not exceed 2.0%.

loss on drying

take this product, dry to constant weight at 105°C, weight loss shall not exceed 1.0% (General rule 0831).

ignition residue

not more than 0.1% (General rule 0841).

Last Update：2022-01-01 11:42:05

ndrostanazol - Content determination

Authoritative Data Verified Data

take this product dry product about 0.27g, precision weighing, add glacial acetic acid 30ml micro heat to dissolve, cool, add crystal violet indicator liquid 1 drop, with perchloric acid titration solution (0.1 mol /L) titration to the solution is green, and the result of the titration is corrected with a blank test. Each 1 ml of perchloric acid titration solution (0.1 mol /L) corresponds to 32.85mg of C21H32N2O.

Last Update：2022-01-01 11:42:06

ndrostanazol - Category

Authoritative Data Verified Data

anabolic hormone drugs.

Last Update：2022-01-01 11:42:06

ndrostanazol - Storage

Authoritative Data Verified Data

light shielding, closed storage.

Last Update：2022-01-01 11:42:06

ndrostanazol - Stanozolol tablets

Authoritative Data Verified Data

This product contains stanozolol (C21H32N20) should be 90% ~ 110.0% of the label amount.

trait

This product is white tablet.

identification

take an appropriate amount of fine powder of this product (equivalent to 2mg of stanozolol), add 5ml of ethanol, heat to boiling in a water bath, filter, and evaporate the filtrate on the water bath, 3ml of p-dimethylaminobenzaldehyde solution was added to the residue, which showed yellow color. The residue was examined under a UV lamp (365nm) and showed yellow-green fluorescence.
in the chromatogram recorded under the content determination item, the retention time of the main peak of the test solution should be consistent with the retention time of the main peak of the reference solution.

examination

Related substances take 25 tablets of this product, grind it, take appropriate amount (about 40mg equivalent to stanozolol), add 15ml of dichloromethane-anhydrous ethanol (9:1); shaking to dissolve stanozolol, rapidly filtering, blowing nitrogen at room temperature to dryness, and dissolving the residue with 3ml of the above solvent as a test solution; tested according to the method under stanozolol related substances. Test solution such as impurity spots, compared with the control solution of the main spot, not deeper, the total amount of impurities should not exceed 2.0%.
Content uniformity take 1 tablet of this product, put it in a 25ml measuring flask, add 1ml of water, shake it to disintegrate, then add 20ml of anhydrous ethanol, sonicate and shake constantly to dissolve stanozolol, let it cool, dilute to scale with absolute ethanol, shake well, rapidly filter, and determine the content according to the method under the content determination item, except for the limit of ± 20%, the provisions (General 0941) shall be met.
the dissolution of this product, according to the dissolution and release determination method (General rule 0931 third method), with hydrochloric acid solution (9-1000) 250ml as the dissolution medium, the rotation speed is 50 rpm, operate according to law, after 45 minutes, take the solution and filter, take the filtrate as the test solution; Take another 20mg of stanozolol reference, weigh it accurately, put it in 50ml measuring flask, add 15ml ethanol, heat in a warm water bath to dissolve, cool, add 1.Omol/L hydrochloric acid solution 5.0ml, diluted with water to the scale, shake well, take 2ml, put it in a 100ml measuring flask, dilute it to the scale with hydrochloric acid solution (9-1000), shake well, as a reference solution (in the new system). The sample solution and the reference solution are each 50 u1, and the dissolution amount of each tablet is calculated according to the method under the content determination item. The limit is 75% of the labeled amount and shall be in accordance with the provisions.
others shall be in accordance with the relevant provisions under the item of tablets (General rule 0101).

Content determination

measured by high performance liquid chromatography (General 0512).
chromatographic conditions and system suitability test using eighteen alkyl silane bonded silica gel as filler; Methanol -0.05mol/L ammonium dihydrogen phosphate solution (75:25) as mobile phase; The detection wavelength was 224mn. The number of theoretical plates is not less than 3500 calculated from the peak of Stanozolol.
determination of 20 tablets of this product, precision weighing, fine grinding, precision weighing an appropriate amount (about 2mg equivalent to stanozolol), put it in a 25ml measuring flask, add an appropriate amount of anhydrous ethanol, sonicate and shake constantly to dissolve stanozolol, let it cool, dilute to scale with absolute ethanol, shake well, rapidly filter, and take continued filtrate as test solution, A 10ul injection liquid chromatograph was accurately measured, and the chromatogram was recorded. Another reference substance of stanozolol was accurately weighed, dissolved and quantitatively diluted with anhydrous ethanol to make a solution containing about 80ug per lml, same method determination. According to the external standard method to calculate the peak area, that is.

specification

2mg

storage

light shielding, closed storage.

Last Update：2022-01-01 11:42:07

ndrostanazol - Reference Information

pharmacological action	kanglilong is anabolic hormone. Its protein assimilation effect is strong, 30 times that of methyltestosterone, while androgen activity is only 1/4 of the latter. This product has the effects of promoting protein synthesis, inhibiting protein heterogenesis, reducing serum cholesterol and triglycerides, promoting calcium and phosphorus deposition and reducing bone marrow suppression. It can also increase physical strength, appetite and weight gain.
Indications	Canolone is clinically used for severe illness and postoperative frail emaciation, the elderly and infirm, as well as various chronic wasting diseases, osteoporosis, pediatric dysplasia, aplastic anemia, leukopenia, thrombocytopenia, hyperlipidemia, etc.
adverse reactions	lower limbs and facial edema may occur at the initial stage of taking medicine. Long-term application may lead to jaundice and liver function damage, which may lead to liver cancer. Some have delayed menstruation and female masculinization.
use	for chronic wasting diseases, serious diseases and postoperative infirmity, old age and infirmity, osteoporosis, dysplasia in children, aplastic anemia, etc. Prevention and treatment of hereditary angioedema
NIST chemical information	The information is: webbook.nist.gov provides (external link)
toxic substance data	The information is: pubchem.ncbi.nlm.nih.gov Provide (external link)

Last Update：2024-04-09 20:48:19

Shanghai Worldyang Chemical Co.,Ltd.

ndrostanazol

Stanozolol

CAS: 10418-03-8

Molecular Formula: C21H32N2O

ndrostanazol - Names and Identifiers

ndrostanazol - Physico-chemical Properties

ndrostanazol - Risk and Safety

ndrostanazol - Standard

Authoritative Data Verified Data

ndrostanazol - Trait

Authoritative Data Verified Data

specific rotation

ndrostanazol - Differential diagnosis

Authoritative Data Verified Data

ndrostanazol - Exam

Authoritative Data Verified Data

Related substances

loss on drying

ignition residue

ndrostanazol - Content determination

Authoritative Data Verified Data

ndrostanazol - Category

Authoritative Data Verified Data

ndrostanazol - Storage

Authoritative Data Verified Data

ndrostanazol - Stanozolol tablets

Authoritative Data Verified Data

trait

identification

examination

Content determination

category

specification

storage

ndrostanazol - Reference Information

Supplier List

ndrostanazol Request for Quotation

Stanozolol

CAS: 10418-03-8

Molecular Formula: C21H32N2O

ndrostanazol - Names and Identifiers

ndrostanazol - Physico-chemical Properties

ndrostanazol - Risk and Safety

ndrostanazol - Standard

Authoritative Data Verified Data

ndrostanazol - Trait

Authoritative Data Verified Data

specific rotation

ndrostanazol - Differential diagnosis

Authoritative Data Verified Data

ndrostanazol - Exam

Authoritative Data Verified Data

Related substances

loss on drying

ignition residue

ndrostanazol - Content determination

Authoritative Data Verified Data

ndrostanazol - Category

Authoritative Data Verified Data

ndrostanazol - Storage

Authoritative Data Verified Data

ndrostanazol - Stanozolol tablets

Authoritative Data Verified Data

trait

identification

examination

Content determination

category

specification

storage

ndrostanazol - Reference Information

Supplier List

ndrostanazol